These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33145274)

  • 1. Repeated radioembolization in advanced liver cancer.
    Masthoff M; Schindler P; Harders F; Heindel W; Wilms C; Schmidt HH; Pascher A; Stegger L; Rahbar K; Wildgruber M; Köhler M
    Ann Transl Med; 2020 Sep; 8(17):1055. PubMed ID: 33145274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Factors for Overall Survival in Advanced Intrahepatic Cholangiocarcinoma Treated with Yttrium-90 Radioembolization.
    Köhler M; Harders F; Lohöfer F; Paprottka PM; Schaarschmidt BM; Theysohn J; Herrmann K; Heindel W; Schmidt HH; Pascher A; Stegger L; Rahbar K; Wildgruber M
    J Clin Med; 2019 Dec; 9(1):. PubMed ID: 31881761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Yttrium-90 Transarterial Radioembolization with Resin Microspheres Prescribed Using the Medical Internal Radiation Dose Model for Intrahepatic Cholangiocarcinoma.
    Sarwar A; Ali A; Ljuboja D; Weinstein JL; Shenoy-Bhangle AS; Nasser IA; Morrow MK; Faintuch S; Curry MP; Bullock AJ; Ahmed M
    J Vasc Interv Radiol; 2021 Nov; 32(11):1560-1568. PubMed ID: 34454031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial Radioembolization of Hepatocellular Carcinoma, Liver-Dominant Hepatic Colorectal Cancer Metastases, and Cholangiocarcinoma Using Yttrium90 Microspheres: Eight-Year Single-Center Real-Life Experience.
    Pellegrinelli J; Chevallier O; Manfredi S; Dygai-Cochet I; Tabouret-Viaud C; Nodari G; Ghiringhelli F; Riedinger JM; Popoff R; Vrigneaud JM; Cochet A; Aho S; Latournerie M; Loffroy R
    Diagnostics (Basel); 2021 Jan; 11(1):. PubMed ID: 33466706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment albumin may aid in patient selection for intrahepatic Y-90 microsphere transarterial radioembolization (TARE) for malignancies of the liver.
    Orwat KP; Beckham TH; Cooper SL; Ashenafi MS; Anderson MB; Guimaraes M; Yamada R; Marshall DT
    J Gastrointest Oncol; 2017 Dec; 8(6):1072-1078. PubMed ID: 29299369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib.
    Teyateeti A; Mahvash A; Long J; Abdelsalam M; Avritscher R; Kaseb A; Odisio B; Ravizzini G; Surasi D; Teyateeti A; Macapinlac H; Kappadath SC
    World J Gastroenterol; 2021 Dec; 27(47):8166-8181. PubMed ID: 35068861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
    Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
    J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: a single center experience.
    Kim AY; Unger K; Wang H; Pishvaian MJ
    BMC Cancer; 2016 Jul; 16():492. PubMed ID: 27430276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer.
    Puleo L; Agate L; Bargellini I; Boni G; Piaggi P; Traino C; Depalo T; Lorenzoni G; Bianchi F; Volterrani D; Brogioni S; Bottici V; Brunetto MR; Coco B; Molinaro E; Elisei R
    Eur Thyroid J; 2022 Dec; 11(6):. PubMed ID: 36126186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes Analysis of 90Y Radioembolization for Tumors Other Than Metastatic Colorectal Cancer from the RESiN (Radiation-Emitting SIR-spheres in Non-resectable liver tumors) Registry.
    Zhou W; Du L; Brown DB; Shah RP; Sze DY
    J Vasc Interv Radiol; 2024 Jul; ():. PubMed ID: 39009301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study.
    Bibok A; Mhaskar R; Jain R; Zhang J; Frakes J; Hoffe S; El-Haddad G; Parikh N; Ahmed A; Fishman MN; Choi J; Kis B
    Cardiovasc Intervent Radiol; 2021 Nov; 44(11):1755-1762. PubMed ID: 34312688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
    El Fouly A; Ertle J; El Dorry A; Shaker MK; Dechêne A; Abdella H; Mueller S; Barakat E; Lauenstein T; Bockisch A; Gerken G; Schlaak JF
    Liver Int; 2015 Feb; 35(2):627-35. PubMed ID: 25040497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection.
    She WH; Cheung TT; Yau TC; Chan AC; Chok KS; Chu FS; Liu RK; Poon RT; Chan SC; Fan ST; Lo CM
    Hepatobiliary Surg Nutr; 2014 Aug; 3(4):185-93. PubMed ID: 25202695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children.
    Aguado A; Ristagno R; Towbin AJ; Gupta A; Haberle S; Qi Z; Patel MN; Kukreja KU; Tiao GM; Geller JI
    Pediatr Blood Cancer; 2019 Jul; 66(7):e27510. PubMed ID: 30406959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization.
    Lee JS; Choi HJ; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baek SE; Chung YE; Park MS; Kim MJ; Rhee H; Kim SU
    Gut Liver; 2020 Nov; 14(6):765-774. PubMed ID: 32050313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiomics-Based Prediction Model for Outcome of Radioembolization in Metastatic Colorectal Cancer.
    Roll W; Masthoff M; Köhler M; Rahbar K; Stegger L; Ventura D; Morgül H; Trebicka J; Schäfers M; Heindel W; Wildgruber M; Schindler P
    Cardiovasc Intervent Radiol; 2024 Apr; 47(4):462-471. PubMed ID: 38416178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases.
    Tomozawa Y; Jahangiri Y; Pathak P; Kolbeck KJ; Schenning RC; Kaufman JA; Farsad K
    J Vasc Interv Radiol; 2018 Jun; 29(6):858-865. PubMed ID: 29724520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
    Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
    Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
    Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
    J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.